RA patients with higher basal serum level of several pro-inflammatory cytokines, including IL-1β, IL-2, and TNF-α, were shown to better respond to tocilizumab, an anti-IL-6R treatment [70]. The gene discussed is IL1B; the disease is rheumatoid arthritis.